Regen BioPharma, Inc.
RGBP · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -46.5% | 0% | 0.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 28.9% | 100% | 100% | 78.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $0 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | -267.5% | -176.3% | -290.4% | -144.4% |
| Other Income/Exp. Net | -$1 | -$0 | $2 | $3 |
| Pre-Tax Income | -$1 | -$1 | $1 | $2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | $1 | $2 |
| % Margin | -1,007% | -282.4% | 432.9% | 945.6% |
| EPS | -0.05 | -0.16 | 0.14 | 0.36 |
| % Growth | 68.8% | -214.3% | -61.1% | – |
| EPS Diluted | -0.05 | -0.16 | 0.14 | 0.36 |
| Weighted Avg Shares Out | 24 | 4 | 7 | 3 |
| Weighted Avg Shares Out Dil | 24 | 4 | 7 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $2 | $0 |
| EBITDA | -$0 | -$0 | $3 | $3 |
| % Margin | -267.5% | -176.7% | 1,318.5% | 1,270.8% |